Cancer-associated venous thrombosis in adults (second edition): A British Society for Haematology Guideline
- PMID: 38664942
- DOI: 10.1111/bjh.19414
Cancer-associated venous thrombosis in adults (second edition): A British Society for Haematology Guideline
Abstract
A shared decision on the most appropriate agent for the treatment of cancer-associated thrombosis should consider the following factors, which should be reassessed as patients continue along their cancer care pathway: risk of bleeding; tumour site; suitability of oral medications; potential for drug-drug interactions; and patient preference and values regarding choice of drug. Continuing anticoagulation beyond 6 months in patients with cancer-associated venous thromboembolism and active cancer is recommended.
Keywords: anticoagulation; cancer; venous thromboembolism; venous thrombosis.
© 2024 British Society for Haematology and John Wiley & Sons Ltd.
References
REFERENCES
-
- Ahmad AS, Ormiston‐Smith N, Sasieni PD. Trends in the lifetime risk of developing cancer in Great Britain: comparison of risk for those born from 1930 to 1960. Br J Cancer. 2015;112(5):943–947.
-
- Horsted F, West J, Grainge MJ. Risk of venous thromboembolism in patients with cancer: a systematic review and meta‐analysis. PLoS Med. 2012;9(7):e1001275.
-
- Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 3rd. Risk factors for deep vein thrombosis and pulmonary embolism: a population‐based case‐control study. Arch Intern Med. 2000;160(6):809–815.
-
- Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006;166(4):458–464.
-
- Sibson KR, Biss TT, Furness CL, Grainger JD, Hough RE, Macartney C, et al. BSH Guideline: management of thrombotic and haemostatic issues in paediatric malignancy. Br J Haematol. 2018;180(4):511–525.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources